Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Japan OKs Honebuto Budget Policy Blueprint, Vows Debates on Longer-Term Drug Costs
The Japanese government on June 16 hammered out its “honebuto” annual budget policy blueprint following a last-minute modification that added a call for discussions on how drug spending should be in the medium to long term. The honebuto paper, formally…
To read the full story
Related Article
- Honebuto Policy Is Tailwind for Pharma, but Situation Remains Unpredictable
June 22, 2023
- LDP Policy Research Council Generally Approves Revised Honebuto Draft
June 14, 2023
- Honebuto Social Security Debate Culminates with LDP Push for Nixing Budget Cap
June 9, 2023
- Draft Honebuto Paper Unveiled, Cabinet OK Expected in Mid-June
June 8, 2023
- Draft Honebuto Paper Calls for Further Drug Pricing Measures to Reward Innovation
June 7, 2023
- LDP Pharma Study Group Proposes Removing Cap for Social Security Costs
May 23, 2023
- LDP Pharma Study Group Eyes Removal of Budget Cap on Social Security Spending
May 11, 2023
REGULATORY
- LDP Lawmakers’ League Urges Continued Coverage for Local Transdermal Analgesics
December 10, 2025
- Senior LDP Lawmakers Call for “Net Plus” in FY2026 Fee, Drug Price Revisions
December 10, 2025
- Japan Govt Council Discusses Draft Recommendations for National MCM Strategy
December 9, 2025
- MHLW Eyes Govt-Led Ingredient Lists for Regional Formularies: LDP Briefing
December 9, 2025
- JMA Pushes Back on Incentives Tied to Regional Formularies: Chuikyo
December 9, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…